IHMT-BMX-068

IHMT-BMX-068 potently degrades BMX protein in H446DDPR cells, with a DC₅₀ of 0.007 μM^[1].
IHMT-BMX-068 potently inhibits the proliferation of DU145, LNCaP clone FGC, 22Rv1 and VCaP prostate cancer cells, with GI₅₀ values of 0.29 μM, 0.83 μM, 1.83 μM and 6.65 μM, respectively; it shows no significant cytotoxicity in normal CHO cells (GI₅₀ > 10 μM)^[1].
IHMT-BMX-068 (1-10 μM; 96 h) inhibits the growth of LNCaP clone FGC cells in a dose-dependent manner at concentrations of 1 μM, 3 μM and 10 μM following 96 h of treatment^[1].
Treatment with IHMT-BMX-068 (0.001-1 μM; 20 h) induces dose-dependent degradation of BMX protein in LNCaP clone FGC cells, with a DC₅₀ of 0.038 μM, and the degradation effect reaches maximum at 0.1 μM^[1].
IHMT-BMX-068 (1-10 μM; 96 h) induces caspase-mediated apoptosis in LNCaP clone FGC cells in a dose-dependent manner. After 96 h of treatment, increased levels of cleaved PARP and cleaved caspase-3 are observed at concentrations of 1 μM, 3 μM, and 10 μM^[1].
IHMT-BMX-068 (0.3-10 μM; 24 h) inhibits the proliferation of LNCaP clone FGC cells in a dose-dependent manner, which is evidenced by the reduced percentages of EdU-positive cells at concentrations of 0.3 μM, 1 μM, 3 μM and 10 μM after 24 h of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.